Gynecologic Cancer

The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.

NRG-GY005 Cediranib + Olaparib combined vs Cediranib or Olaparib alone, or standard of care chemo, recurrent platinum resistant or refractory ovarian, fallopian or primary peritoneal ca.

Study Details

  • Study Site/Tumor Location: Gynecology
  • Study Location: Miami Valley Hospital South Campus
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Female
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information